VERV241220C12500
- 0.05
- 0.000.00%
Verve Therapeutics Newsroom
RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17
J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23
CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32
RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating
Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Verve Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Verve Therapeutics(VERV.US), With a Forecast Between $14 to $23
Verve Therapeutics Price Target Cut to $29.00/Share From $30.00 by Canaccord Genuity
Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
Verve Therapeutics Analyst Ratings
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
Verve Therapeutics Analyst Ratings
Buy Rating Affirmed for Verve Therapeutics With Strategic Focus on Promising VERVE-102 Program